RxDoctor Payments Data

Katlyn Amason, NP

Gerontology · Flowood, MSNPI 1144854498

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,612 of the $4,502 with a category attached, or 80.2%. 32 manufacturers reported payments, led by Teleflex LLC at 25.5% of the total.

$4,502in general payments, 2019–2025

Across 172 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Sumitomo Pharma America, Inc.$544
  • Johnson & Johnson$347
  • Smith+Nephew$258
  • Dendreon Pharmaceuticals LLC$246
  • Astellas Pharma US Inc$237
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$79118%
  • Food & beverage$3,61280%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,502 in reported general payments places this provider in the 85th percentile of 66 gerontology providers in Mississippi.

See all gerontology providers in Mississippi

Medicare billing

Part B allowed, 2024
$317,748
Medicare patients
848
Services billed
11,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron52$37,648
MyrbetriqMirabegron17$10,487
Tamsulosin Hcl399$4,385
Dutasteride149$3,131
NitrofurantoinNitrofurantoin Macrocrystal107$2,548
Estradiol40$2,500
Meropenem15$2,342
Methenamine Hippurate29$1,507
Ciprofloxacin Hcl179$1,115
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst52$787
Tolterodine Tartrate ErTolterodine Tartrate13$679
Finasteride60$590
CefuroximeCefuroxime Axetil27$569
Levofloxacin38$547
Potassium Citrate ErPotassium Citrate12$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$544$37,64852 claims
Astellas Pharma US IncMyrbetriq$237$10,48717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 66 gerontology providers in Mississippi.

Other gerontology in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →